cyclobutyl 9-(6-(2-chloro-4-cyanophenylamino)-5-fluoropyrimidin-4-yloxy)-3-oxa-7-azabicyclo[3.3.1]nonane-7-carboxylate

ID: ALA4163003

Chembl Id: CHEMBL4163003

PubChem CID: 68036931

Max Phase: Preclinical

Molecular Formula: C23H23ClFN5O4

Molecular Weight: 487.92

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  N#Cc1ccc(Nc2ncnc(OC3C4COCC3CN(C(=O)OC3CCC3)C4)c2F)c(Cl)c1

Standard InChI:  InChI=1S/C23H23ClFN5O4/c24-17-6-13(7-26)4-5-18(17)29-21-19(25)22(28-12-27-21)34-20-14-8-30(9-15(20)11-32-10-14)23(31)33-16-2-1-3-16/h4-6,12,14-16,20H,1-3,8-11H2,(H,27,28,29)

Standard InChI Key:  UVZZEDRNPHNBFJ-UHFFFAOYSA-N

Associated Targets(Human)

GPR119 Tclin Glucose-dependent insulinotropic receptor (4762 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Gpr119 Glucose-dependent insulinotropic receptor (559 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 487.92Molecular Weight (Monoisotopic): 487.1423AlogP: 3.90#Rotatable Bonds: 5
Polar Surface Area: 109.60Molecular Species: NEUTRALHBA: 8HBD: 1
#RO5 Violations: HBA (Lipinski): 9HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 10.25CX Basic pKa: 2.59CX LogP: 3.68CX LogD: 3.68
Aromatic Rings: 2Heavy Atoms: 34QED Weighted: 0.68Np Likeness Score: -1.04

References

1. Neelamkavil SF, Stamford AW, Kowalski T, Biswas D, Boyle C, Chackalamannil S, Xia Y, Jayne C, Neustadt B, Hao J, Liu H, Dai X, Baker H, Hawes B, O'Neill K, Tang H, Greenlee WJ..  (2018)  Discovery of MK-8282 as a Potent G-Protein-Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes.,  (5): [PMID:29795759] [10.1021/acsmedchemlett.8b00073]

Source